Ciprofol reduces postoperative glioma recurrence by promoting MAPK11-PML phosphorylation: insights from transcriptomic and proteomic analysis
Journal of Neuro-Oncology · 2025
DOI: 10.1007/s11060-024-04906-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuro-Oncology, 2025. Verfasst von Yanli Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China. Hauptthemen laut MEDLINE: Glioma, Neoplasm Recurrence, Local, Brain Neoplasms. Die Arbeit nennt 55 Literaturangaben. Gefördert von: Key Research Project of Hebei Provincial Health Commission.
Abstract (Originalsprache)
BACKGROUND: Glioma, the most common malignant tumor of the central nervous system, has a high postoperative recurrence rate. While Ciprofol is widely used as an anesthetic, its therapeutic potential in glioma treatment remains largely unexplored. METHODS: Glioma T98G cells were treated with varying concentrations of Ciprofol to assess proliferation, invasion, migration, and apoptosis via CCK-8, Transwell, and flow cytometry assays. Proteomic, phosphoproteomic, and transcriptomic analyses were performed to identify molecular targets and pathways. Molecular docking evaluated the binding of Ciprofol to key kinases, and silencing experiments validated their roles. In vivo, glioma mouse models were used to assess postoperative recurrence via tumor size, fluorescence imaging, and histological analysis. RESULTS: Ciprofol inhibited glioma cell proliferation, invasion, and migration while promoting apoptosis. Proteomic analyses identified MAPK11 and PML as key mediators of Ciprofol's effects. Silencing MAPK11 impaired these effects, while in vivo experiments showed reduced postoperative recurrence via MAPK11-PML phosphorylation. CONCLUSION: Ciprofol reduces postoperative glioma recurrence by promoting MAPK11-PML phosphorylation, providing novel molecular targets for glioma treatment and suggesting its therapeutic potential beyond anesthesia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
- Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, NO.12, JianKang Road, Shijiazhuang, 050011, Hebei, China.
- Department of Anesthesiology and Intensive Care, The Second Hospital of Hebei Medical University, Shijiazhuang, 050000, China.
- Department of Anesthesiology, The Fourth Hospital of Hebei Medical University, NO.12, JianKang Road, Shijiazhuang, 050011, Hebei, China. jysyjiahuiqun@163.com.
Förderung
- Key Research Project of Hebei Provincial Health Commission
Zitieren
APA
Li, Y., Shi, J., Liu, C., Ma, D., Meng, L., Zhang, Z., & Jia, H. (2025). Ciprofol reduces postoperative glioma recurrence by promoting MAPK11-PML phosphorylation: insights from transcriptomic and proteomic analysis. Journal of Neuro-Oncology. https://doi.org/10.1007/s11060-024-04906-w
Vancouver
Li Y, Shi J, Liu C, Ma D, Meng L, Zhang Z, et al. Ciprofol reduces postoperative glioma recurrence by promoting MAPK11-PML phosphorylation: insights from transcriptomic and proteomic analysis. Journal of Neuro-Oncology. 2025. doi:10.1007/s11060-024-04906-w
BibTeX
@article{Li2025,
author = {Li, Yanli and Shi, Jingpu and Liu, Chao and Ma, Dongyang and Meng, Lijiang and Zhang, Zhiqiang and Jia, Huiqun},
title = {Ciprofol reduces postoperative glioma recurrence by promoting MAPK11-PML phosphorylation: insights from transcriptomic and proteomic analysis},
journal = {Journal of Neuro-Oncology},
year = {2025},
doi = {10.1007/s11060-024-04906-w}
}
EUVIMED